Biliary tract cancer: current challenges and future prospects

References

• ValleJWAdvances in the treatment of metastatic or unresectable biliary tract cancerAnn Oncol201021Suppl 7vii345vii34820943640
   PubMedGoogle Scholar
• KimSJAkitaMSungYNMDM2 Amplification in intrahepatic cholangiocarcinomas: its relationship with large-duct type morphology and uncommon KRAS mutationsAm J Surg Pathol201842451252129309301
   PubMed Web of Science ®Google Scholar
• GLOBOCAN [homepage on the Internet]2012 v.10, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11International Agency for Research on Cancer2013 Available from: http://globocan.iarc.frAccessedAugust 1, 2018
   Google Scholar
• ShaibYEl-SeragHBThe epidemiology of cholangiocarcinomaSemin Liver Dis200424211512515192785
   PubMed Web of Science ®Google Scholar
• HundalRShafferEAGallbladder cancer: epidemiology and outcomeClin Epidemiol201469910924634588
   PubMed Web of Science ®Google Scholar
• HarringtonJCarterLBasuBCookNDrug development and clinical trial design in pancreatico-biliary malignanciesCurr Probl Cancer2018421739429402439
   PubMed Web of Science ®Google Scholar
• HorganAMAmirEWalterTKnoxJJAdjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysisJ Clin Oncol201230161934194022529261
   PubMed Web of Science ®Google Scholar
• EndoIGonenMYoppACIntrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resectionAnn Surg20082481849618580211
   PubMed Web of Science ®Google Scholar
• ValleJWBorbathIKhanSABiliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201627Suppl 5v28v3727664259
   PubMed Web of Science ®Google Scholar
• ValleJWLamarcaAGoyalLBarriusoJZhuAXNew horizons for precision medicine in biliary tract cancersCancer Discov20177994396228818953
   PubMed Web of Science ®Google Scholar
• SquadroniMTondulliLGattaGMosconiSBerettaGLabiancaRCholangiocarcinomaCrit Rev Oncol Hematol2017116113128693792
   PubMed Web of Science ®Google Scholar
• TakadaTAmanoHYasudaHIs postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pan-creaticobiliary carcinomaCancer20029581685169512365016
   PubMed Web of Science ®Google Scholar
• GhidiniMTomaselloGBotticelliAAdjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysisHPB (Oxford)201719974174828684194
   PubMed Web of Science ®Google Scholar
• EbataTHiranoSKonishiMRandomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancerBr J Surg2018105319220229405274
   PubMed Web of Science ®Google Scholar
• EdelineJBonnetainFPhelipJMGemox versus surveillance following surgery of localized biliary tract cancer: results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trialJ Clin Oncol2017354 Suppl225
   Web of Science ®Google Scholar
• PrimroseJNFoxRPalmerDHAdjuvant capecitabine for biliary tract cancer: the BILCAP randomized studyJ Clin Oncol20173515 Suppl4006
   Google Scholar
• BridgewaterJFoxRPrimroseJTBS GroupExploratory analyses of the BILCAP study2018ASCO Annual Meeting2018Chicago
   Google Scholar
• SteinAArnoldDBridgewaterJAdjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial): a randomized, multidisciplinary, multinational phase III trialBMC Cancer20151556426228433
   PubMed Web of Science ®Google Scholar
• PhelipJMVendrelyVRostainFGemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised studyEur J Cancer201450172975298225241229
   PubMed Web of Science ®Google Scholar
• TaoRKrishnanSBhosalePRAblative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: a retrospective dose response analysisJ Clin Oncol201634321922626503201
   PubMed Web of Science ®Google Scholar
• EdelineJDuFLRayarMGlass microspheres 90Y selective internal radiation therapy and chemotherapy as first-line treatment of intrahepatic cholangiocarcinomaClin Nucl Med2015401185185526204219
   PubMed Web of Science ®Google Scholar
• Al-AdraDPGillRSAxfordSJShiXKnetemanNLiauSSTreatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysisEur J Surg Oncol201541112012725449754
   PubMed Web of Science ®Google Scholar
• ValleJWasanHPalmerDHCisplatin plus gemcitabine versus gemcitabine for biliary tract cancerN Engl J Med2010362141273128120375404
   PubMed Web of Science ®Google Scholar
• MorizaneCOkusakaTMizusawaJRandomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer: a Japan Clinical Oncology Group study (JCOG1113, FUGA-BT)J Clin Oncol2018364 Suppl205205
   Web of Science ®Google Scholar
• LamarcaAHubnerRADavid RyderWValleJWSecond-line chemotherapy in advanced biliary cancer: a systematic reviewAnn Oncol201425122328233824769639
   PubMed Web of Science ®Google Scholar
• ZhengYTuXZhaoPA randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatinBr J Cancer2018119329129529955136
   PubMed Web of Science ®Google Scholar
• SimboloMFassanMRuzzenenteAMultigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroupsOncotarget2014592839285224867389
   PubMedGoogle Scholar
• NakamuraHAraiYTotokiYGenomic spectra of biliary tract cancerNat Genet20154791003101026258846
   PubMed Web of Science ®Google Scholar
• ZouJWangCMaXWangEPengGAPOBEC3B, a molecular driver of mutagenesis in human cancersCell Biosci201772928572915
   PubMed Web of Science ®Google Scholar
• ZouSLiJZhouHMutational landscape of intrahepatic chol-angiocarcinomaNat Commun20145569625526346
   PubMed Web of Science ®Google Scholar
• SiaDLosicBMoeiniAMassive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinomaNat Commun20156608725608663
   PubMed Web of Science ®Google Scholar
• LiMZhangZLiXWhole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathwayNat Genet201446887287624997986
   PubMed Web of Science ®Google Scholar
• GaldySLamarcaAMcnamaraMGHER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?Cancer Metastasis Rev201736114115727981460
   PubMed Web of Science ®Google Scholar
• YoshikawaDOjimaHIwasakiMClinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinomaBr J Cancer200898241842518087285
   PubMed Web of Science ®Google Scholar
• ChenWLiangJHuangLCharacterizing the activation of the Wnt signaling pathway in hilar cholangiocarcinoma using a tissue microarray approachEur J Histochem2016601253626972709
   PubMed Web of Science ®Google Scholar
• MiyamotoMOjimaHIwasakiMPrognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinomaBr J Cancer2011105113113821673683
   PubMed Web of Science ®Google Scholar
• LeeJParkSHChangHMGemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 studyLancet Oncol201213218118822192731
   PubMed Web of Science ®Google Scholar
• LeoneFMarinoDCeredaSPanitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: a randomized phase 2 trial (Vecti-BIL study)Cancer2016122457458126540314
   PubMed Web of Science ®Google Scholar
• FerraroDGoldsteinDO’ConnellRLTACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancerCancer Chemother Pharmacol201678236136727335026
   PubMed Web of Science ®Google Scholar
• VogelAKasperSBitzerMPICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO studyEur J Cancer201892111929413685
   PubMed Web of Science ®Google Scholar
• MalkaDCerveraPFoulonSGemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trialLancet Oncol201415881982824852116
   PubMed Web of Science ®Google Scholar
• ChenJSHsuCChiangNJA KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancerAnn Oncol201526594394925632066
   PubMed Web of Science ®Google Scholar
• IyerRVPokuriVKGromanAA multicenter Phase II study of gemcitabine, capecitabine, and bevacizumab for locally advanced or metastatic biliary tract cancerAm J Clin Oncol201841764965527849649
   PubMed Web of Science ®Google Scholar
• LarsenFOMarkussenADinessLVNielsenDEfficacy and safety of capecitabine, irinotecan, gemcitabine, and bevacizumab as second-line treatment in advanced biliary tract cancer: a Phase II cancer: A Phase II StudyOncology20189411924
   PubMed Web of Science ®Google Scholar
• MizrahiJJavleMMXiaoLA phase II study of ramucirumab for advanced, pre-treated biliary cancers2018ASCO Annual Meeting2018Chicago
   Google Scholar
• ValleJWWasanHLopesACediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trialLancet Oncol201516896797826179201
   PubMed Web of Science ®Google Scholar
• MoehlerMMadererASchimanskiCGemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programmeEur J Cancer201450183125313525446376
   PubMed Web of Science ®Google Scholar
• YiJHThongprasertSLeeJA phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational studyEur J Cancer201248219620122176869
   PubMed Web of Science ®Google Scholar
• NeuzilletCSeitzJFFartouxLSunitinib as second-line treatment in patients with advanced intrahepatic cholangiocarcinoma (SUN-CK phase II trial): safety, efficacy, and updated translational resultsJ Clin Oncol2015333 Suppl343343
   Web of Science ®Google Scholar
• SantoroAGebbiaVPressianiTA randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh studyAnn Oncol201526354254725538178
   PubMed Web of Science ®Google Scholar
• DohertyMTamVCMcnamaraMGSelumetinib (Sel) and cisplatin/gemcitabine (CisGem) for advanced biliary tract cancer (BTC): a randomized trialJ Clin Oncol20183615 Suppl40844084
   Web of Science ®Google Scholar
• GoyalLZhengHYurgelunMBA phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinomaCancer2017123111979198828192597
   PubMed Web of Science ®Google Scholar
• IkedaMIokaTFukutomiAEfficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabineCancer Sci2018109121522429121415
   PubMed Web of Science ®Google Scholar
• ShroffRTYarchoanMO’ConnorAThe oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinomaBr J Cancer2017116111402140728441383
   PubMed Web of Science ®Google Scholar
• GoldsteinDLemechCValleJNew molecular and immunotherapeutic approaches in biliary cancerESMO Open20172Suppl 1e00015228848675
   PubMedGoogle Scholar
• FontugneJAugustinJPujalsAPD-L1 expression in perihilar and intrahepatic cholangiocarcinomaOncotarget2017815246442465128445951
   PubMedGoogle Scholar
• BangYJDoiTBraudFD525 Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028Eur J Cancer201551S112
   PubMed Web of Science ®Google Scholar
• ArkenauHTMartin-LiberalJCalvoERamucirumab plus pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: nonrandomized, open-label, phase I trial (JVDF)Oncologist2018 theoncologist.2018.0044
   Web of Science ®Google Scholar
• SahaiVGriffithKABegMSZalupskiMA multi-center random-ized phase II study of nivolumab in combination with gemcitabine/ cisplatin or ipilimumab as first line therapy for patients with advanced unresectable biliary tract cancerJ Clin Oncol20183615 SupplTPS4142TPS541
   Web of Science ®Google Scholar
• BarettiMDurhamJNWalkerREntinostat in combination with nivolumab for patients with advanced cholangiocarcinoma and pancreatic adenocarcinoma2018Asco Annual Meeting2018Chicago
   Google Scholar
• SahaSKGordanJDKleinstiverBPIsocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinomaCancer Discov20166772773927231123
   PubMed Web of Science ®Google Scholar
• JavleMLoweryMShroffRTPhase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinomaJ Clin Oncol201836327628229182496
   PubMed Web of Science ®Google Scholar
• AssenatEGuimbaudRFraisseJA multicenter phase Ib-IIR trial assessing the activity of regorafenib combined with modified gemcitabine: oxaliplatin (mGEMOX) in patients with advanced biliary tract cancer (aBTC)J Clin Oncol20183615 Supple16134e16134
   Web of Science ®Google Scholar
• SamaARDenlingerCSVogelAGemcitabine and cisplatin plus ramucirumab or merestinib or placebo in first-line treatment for advanced or metastatic biliary tract cancer: a double-blind, randomized phase II trialJ Clin Oncol2017354 SupplTPS509TPS509
   Web of Science ®Google Scholar